Systemic treatment of severe acne with a retinoic acid derivative, isotretinoin.
Twenty-eight patients with severe acne and one with hidradenitis suppurativa and acne were treated for 12 to 16 weeks with a new synthetic retinoid, isotretinoin (Roaccutane). The average dose was 0.56 mg/kg/day. Patients were seen weekly for four weeks and then fortnightly for the remaining treatment period, being evaluated both qualitatively and quantitatively. Twenty-five patients had an excellent response. Two to five months after the end of treatment no patient had relapsed. No patient withdrew because of side effects, but all suffered dry lips. This study confirms the potential of isotretinoin in the treatment of severe acne.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000208:Acute Disease; D000328:Adult; D002214:Capsules; D002613:Cheilitis / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015474:Isotretinoin; D008297:Male; D013997:Time Factors; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D002214:Capsules; D014212:Tretinoin; D015474:Isotretinoin